Observational studyBMC health services research2025
Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran.
Observational study in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNo research has assessed the comprehensive annual costs of managing ulcerative colitis (UC) patients undergoing biological treatment. This study aimed to determine the annual costs and primary cost drivers for UC patients receiving biological therapy.
methodsThis prospective observational study was conducted in Iran from a societal perspective, employing the cost-of-illness method, grounded in human capital theory. A prevalence-based approach and bottom-up technique were used for cost estimation. Inpatient costs were extracted from hospital records, while outpatient service usage and direct non-medical costs over a one-year follow-up were collected through patient interviews. Indirect costs were evaluated using a standardized questionnaire. The average costs per patient were calculated, and the factors affecting patient expenses were analyzed using the Mann-Whitney and Kruskal-Wallis statistical tests.
resultsThe study included 238 UC patients (50.8% male; mean age: 37.66 ± 12.13 years), with 32.8% receiving Infliximab (IFX) and 67.2% on Adalimumab (ADA), and an average disease duration of 9.29 ± 6.5 years. The total annual economic burden per UC patient was USD 2316.90. Of this, direct medical costs constituted 49.84%, direct non-medical costs 21.13%, and indirect costs 29.03%. Notably, higher expenses were significantly associated with patients under 20 years of age and those treated with ADA.
conclusionsBiological therapies accounted for the largest share of direct medical expenses, while productivity losses, mainly resulting from temporary absenteeism, were identified as a major factor contributing to the economic burden of UC in Iran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.